Now Reading: Bharat Biotech, Gavi, UNICEF cut malaria vaccine price 40%
-
01
Bharat Biotech, Gavi, UNICEF cut malaria vaccine price 40%
The Story in Brief
Bharat Biotech International (BBIL) will cut the price of its malaria vaccine Mosqivac by approximately 40 per cent to EUR 5.50 per dose under an agreement executed by UNICEF and financially backed by Gavi. The reduction, effective from early 2027, is expected to generate about $50 million in savings for child immunisation programmes between 2027 and 2029 and allow up to one million more children to receive the full four-dose course.
The RTS,S/AS01 vaccine, developed by GSK and recommended by the WHO in 2021, is now produced by BBIL following technology transfer. GSK and BBIL have invested $200 million in higher-output manufacturing and product development. Demand for malaria vaccines has exceeded initial forecasts since rollout began in 2024, UNICEF has procured and delivered over 74 million doses. Gavi-funded programmes are now part of routine immunisation in 25 African countries, which bear more than 70 per cent of the global malaria burden.
Gavi aims to vaccinate an additional 50 million children against malaria by 2030.
Indian Opinion Analysis
Both outlets wrote straight news summaries of the Gavi-UNICEF-Bharat Biotech pricing agreement, differing only in detail selection. The Hindu Business Line led with Bharat Biotech's announcement and included executive quotes from Krishna Ella and GSK's chief global health officer. Business Standard led with the price cut itself and added background malaria burden data (282 million cases, 610,000 deaths in 2024) and efficacy figures for the four-dose course. Neither source steered coverage toward or against the government, both presented the deal, the price reduction to EUR 5.50 per dose, the $50 million in projected savings and the target of vaccinating 50 million more children by 2030 without evaluative framing. The uniform reporting leaves no stance difference to analyse. The central question the two accounts leave open is whether the EUR 5.50 per dose price, effective early 2027, will sustain as global health aid declines.
Coverage: 2 sources, 2 neutral
Sources (2): thehindubusinessline.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
